Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» BeiGene
BeiGene
ESMO 2022 – the new liver cancer entrants line up
EP Vantage
Thu, 09/8/22 - 10:39 am
ESMO
liver cancer
Keytruda
tislelizumab
camrelizumab
Merck
BeiGene
Novartis
BeiGene and Novartis Make Late-Stage Progress against Liver Cancer
BioSpace
Tue, 08/9/22 - 12:14 pm
Novartis
BeiGene
hepatocellular carcinoma
liver cancer
clinical trials
FDA Indefinitely Delays BeiGene/Novartis anti-PD-1 Esophageal Cancer Drug
BioSpace
Thu, 07/14/22 - 10:51 am
Novartis
BeiGene
FDA
tislelizumab
esophageal cancer
Doubling down on mRNA, BeiGene taps rising Hong Kong star to create targeted therapies
Fierce Biotech
Wed, 07/6/22 - 10:52 am
BeiGene
MRNA
drug discovery
Strand Therapeutics
InnoRNA
R&D
Novartis, BeiGene lay out frontline PhIII data for PD-1 drug as second-line PDUFA date looms
Endpoints
Thu, 06/30/22 - 12:11 pm
Novartis
BeiGene
FDA
tislelizumab
gastrointestinal cancer
BeiGene Reports Lucrative Q1 Amid SEC Audit
BioSpace
Sun, 05/8/22 - 12:08 pm
BeiGene
earnings
Novartis records another tislelizumab win en route to bringing BeiGene's PD-1 to FDA's doors
Endpoints
Wed, 04/27/22 - 10:32 am
Novartis
BeiGene
tislelizumab
esophageal cancer
Outside of big pharma, life remains tough for listed developers
EP Vantage
Wed, 04/20/22 - 10:38 am
pharma stocks
AbbVie
AstraZeneca
BeiGene
BioNTech
Moderna Therapeutics
Pfizer
Roche
JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor
Fierce Biotech
Wed, 01/12/22 - 11:12 am
JPMHC 2022
BeiGene
Ionis Pharmaceuticals
Roche
devices
AstraZeneca
Biogen
Novartis Deepens BeiGene Oncology Pact, Posts Disappointing Results in CSU
BioSpace
Mon, 12/20/21 - 10:49 am
Novartis
BeiGene
China
ociperlimab
anti-TIGIT
Biotech BeiGene slides in Shanghai after $3.5 bln STAR debut
Yahoo/Reuters
Wed, 12/15/21 - 10:39 am
BeiGene
STAR market
China
Shanghai
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
licensing
GSK
Alector
Novartis
BeiGene
Pfizer
Arvinas
iTeos Therapeutics
Bristol Myers Squibb
Eisai
ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again
Fierce Biotech
Thu, 11/4/21 - 10:27 am
BeiGene
Brukinsa
leukemia
clinical trials
AbbVie
JNJ
Imbruvica
Bristol Myers Squibb is nixing BeiGene's Abraxane deal in China amid manufacturing woes. Is their cancer rivalry really to blame?
Fierce Pharma
Thu, 10/14/21 - 11:09 am
cancer
Bristol Myers Squibbe
BeiGene
Abraxane
China
drug manufacturing
FDA grants BeiGene's Brukinsa accelerated approval in marginal zone lymphoma
Seeking Alpha
Wed, 09/15/21 - 11:00 am
BeiGene
Brukinsa
FDA
accelerated approvals
marginal zone lymphoma
First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab
Pharmaforum
Mon, 09/13/21 - 10:26 am
Novartis
tiselizumab
FDA
esophageal cancer
BeiGene
FDA approves BeiGene's Brukinsa in rare blood cancer amid company's US expansion plans
Endpoints
Thu, 09/2/21 - 10:29 am
BeiGene
Brukinsa
blood cancer
FDA
Life Sciences Companies Expand Their Footprints in the US and Canada
BioSpace
Thu, 08/19/21 - 12:02 am
life sciences
United States
Canada
Rentschler Biopharma
Moderna Therapeutics
Precision NanoSystems
BeiGene
Aro Biotherapeutics
Evotec
BeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa win
Fierce Pharma
Mon, 08/2/21 - 10:57 am
BeiGene
Brukinsa
CLL
small lymphocytic lymphoma
clinical trials
Five Collaborations Unlocking Faster Drug Development this Week
BioSpace
Thu, 06/10/21 - 11:12 am
drug development
MannKind
Thirona Bio
pulmonary fibrosis
Oyster Point Pharma
Adaptive Phage Therapeutics
ophthalmic
Takeda
Codexis
ALX Oncology
Eli Lilly
clinical trials
BeiGene
Shoreline Biosciences
oncology
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »